Burney Co. Sells 4,612 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Burney Co. lessened its holdings in Dynavax Technologies Co. (NASDAQ:DVAX) by 19.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,649 shares of the biopharmaceutical company’s stock after selling 4,612 shares during the quarter. Burney Co.’s holdings in Dynavax Technologies were worth $238,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC raised its position in Dynavax Technologies by 175.5% during the third quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 1,685 shares in the last quarter. US Bancorp DE raised its position in Dynavax Technologies by 291.4% during the third quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 2,034 shares in the last quarter. Capital Performance Advisors LLP bought a new stake in Dynavax Technologies during the third quarter worth $45,000. Nisa Investment Advisors LLC raised its position in Dynavax Technologies by 44.6% during the third quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 1,679 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB bought a new stake in Dynavax Technologies during the third quarter worth $89,000. Institutional investors own 96.96% of the company’s stock.

Wall Street Analyst Weigh In

DVAX has been the topic of several analyst reports. HC Wainwright upped their price target on shares of Dynavax Technologies from $29.00 to $31.00 and gave the stock a “buy” rating in a research report on Tuesday, January 14th. StockNews.com raised shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday, January 14th.

Dynavax Technologies Price Performance

Shares of DVAX opened at $12.45 on Friday. The firm has a market capitalization of $1.64 billion, a PE ratio of 95.78 and a beta of 1.34. The company’s 50-day moving average is $12.76 and its 200-day moving average is $11.68. Dynavax Technologies Co. has a fifty-two week low of $9.74 and a fifty-two week high of $14.30. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.